Financial Performance Expectations - The company expects a net profit attributable to shareholders of approximately 16 million to 20.8 million yuan for the year 2024, representing a decrease of 81.46% compared to the same period last year, where it was 112.18 million yuan [3]. - The net loss after deducting non-recurring gains and losses is estimated to be between 7.2 million to 12 million yuan, a decline of 108.04% from the previous year's profit of 89.61 million yuan [3]. - Non-recurring gains and losses are expected to impact net profit by approximately 28 million yuan, mainly from investment income generated by financial products during the reporting period [7]. - The financial data in the performance forecast has not been audited by the accounting firm, and the final figures will be disclosed in the 2024 annual report [8]. Reasons for Performance Decline - The primary reason for the performance decline is the significant drop in the price of lipoic acid products due to increased competition in the domestic and international markets [5]. Strategic Adjustments - The company has adjusted its R&D strategy, focusing more on traditional pharmaceutical health products, leading to the sale of certain obsolete equipment and recognition of related losses [6][7].
富士莱(301258) - 2024 Q4 - 年度业绩预告